Targeting IRG1 in tumor-associated macrophages for cancer therapy

Shuang Liu; Lin-Xing Wei; Qian Yu; Zhi-Wei Guo; Chang-You Zhan; Lei-Lei Chen; Yan Li; Dan Ye

doi:10.1093/procel/pwaf012

Protein Cell ›› 2025, Vol. 16 ›› Issue (6) : 478 -483. DOI: 10.1093/procel/pwaf012

LETTER

Targeting IRG1 in tumor-associated macrophages for cancer therapy

Author information +

History +

PDF (19177KB)

Cite this article

Download citation ▾

Shuang Liu, Lin-Xing Wei, Qian Yu, Zhi-Wei Guo, Chang-You Zhan, Lei-Lei Chen, Yan Li, Dan Ye. Targeting IRG1 in tumor-associated macrophages for cancer therapy. Protein Cell, 2025, 16(6): 478-483 DOI:10.1093/procel/pwaf012

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Akinc A, Maier MA, Manoharan M et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol 2019;14:1084–1087.

[2]	Allen TM, Brehm MA, Bridges S et al. Humanized immune system mouse models: progress, challenges and opportunities. Nat Immunol 2019;20:770–774.

[3]	Chen H, Pan Y, Zhou Q et al. METTL3 inhibits antitumor immunity by targeting m⁶A-BHLHE41-CXCL1/CXCR2 axis to promote colorectal cancer. Gastroenterology 2022a;163:891–907.

[4]	Chen LL, Morcelle C, Cheng ZL et al. Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses. Nat Cell Biol 2022b;24:353–363.

[5]	Chen YJ, Li GN, Li XJ et al. Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy. Sci Adv 2023;9:eadg0654.

[6]	Chuprin J, Buettner H, Seedhom MO et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol 2023;20:192–206.

[7]	Cosgun KN, Rahmig S, Mende N et al. Kit regulates HSC engraftment across the human-mouse species barrier. Cell Stem Cell 2014;15:227–238.

[8]	Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther 2017;25:1467–1475.

[9]	Gu X, Wei H, Suo C et al. Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of CD8⁺ T-cell exhaustion. Nat Commun 2023;14:8154.

[10]	Luo Q, Dong Z, Xie W et al. Apatinib remodels the immuno-suppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy. Cell Rep 2023;42:112437.

[11]	Mills EL, Ryan DG, Prag HA et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 2018;556:113–117.

[12]	Ye D, Wang P, Chen LL et al. Itaconate in host inflammation and defense. Trends Endocrinol Metab 2024;35:586–606.

[13]	Zhai J, Chen H, Wong CC et al. ALKBH5 drives immune suppression via targeting AXIN2 to promote colorectal cancer and is a target for boosting immunotherapy. Gastroenterology 2023;165:445–462.

[14]	Zhao H, Teng D, Yang L et al. Myeloid-derived itaconate suppresses cytotoxic CD8⁺ T cells and promotes tumour growth. Nat Metab 2022;4:1660–1673.